连续多巴胺D2受体阻断与首发精神分裂症的长期结局
基于芬兰全国性队列1996—2014年≤45岁首发精神分裂症患者数据,305例在随访前30天启动并持续使用长效注射抗精神病药者,10年累计复发概率为45%(95%CI=35-57)。年复发率从第1年0.26降至第5年0.05(IRR=0.18),第6—10年每128人年仅4次复发(IRR=0.12)。作者认为持续D2阻断未增加突破性精神病风险。
要点
- 305例持续使用长效注射抗精神病药的首发精神分裂症患者10年累计复发概率为45%(95%CI=35-57)。
- 年复发率从第1年0.26降至第5年0.05,对应IRR=0.18(95%CI=0.04-0.74)。
- 第6—10年128人年仅4次复发,与第1年相比IRR=0.12(95%CI=0.03-0.33)。
核心结论
- 约40%—50%的首发精神分裂症患者尽管接受持续D2阻断仍会复发,作者认为这似乎源于疾病病理生理中的非多巴胺能因素。
- 结果显示长期多巴胺受体阻断与突破性精神病风险增加无关。
研究设计与样本
- 基于芬兰全国性住院登记数据,纳入1996—2014年所有年龄≤45岁的首发精神分裂症患者。
- 主要结局为持续使用长效注射抗精神病药者中导致住院的严重复发;次要结局为以第1年为参照的第2—10年复发发生率比(IRR)。
主要发现
- 共305例患者在随访前30天内启动并确保长效注射抗精神病药使用。
- Kaplan-Meier分析显示10年随访期间累积复发概率为45%(95%CI=35-57)。
- 年复发率从第1年0.26(95%CI=0.20-0.35)降至第5年0.05(95%CI=0.01-0.19),对应IRR=0.18(95%CI=0.04-0.74)。
- 第6—10年128人年中仅发生4次复发,与第1年相比IRR=0.12(95%CI=0.03-0.33)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: It is not known what proportion of patients experience relapse in first-episode schizophrenia despite continuous dopamine D2 receptor blockade and whether breakthrough psychosis is attributable to long-term use of D2-blocking antipsychotics. Using data from a Finnish nationwide cohort, the authors sought to test the hypothesis that the incidence of breakthrough psychosis is accelerated among previously relapse-free patients receiving continuous D2 antagonist treatment beyond 5 years. METHODS: All persons age 45 years or younger with first-episode schizophrenia were identified from the nationwide registry of inpatient care for the years 1996-2014. The primary outcome was a severe relapse leading to hospitalization among those treated continuously with long-acting injectable (LAI) antipsychotics. The secondary outcome was the incidence rate ratio (IRR) of relapse during years 2-10, using year 1 as the reference. RESULTS: A total of 305 patients initiated ensured LAI use during the first 30 days of follow-up. Kaplan-Meier analysis showed that during the 10-year follow-up, their cumulative probability of relapse was 45% (95% CI=35-57). The annual relapse incidence per person-year decreased from 0.26 (95% CI=0.20-0.35) during the first year to 0.05 (95% CI=0.01-0.19) during the fifth year, corresponding to an IRR of 0.18 (95% CI=0.04-0.74). During years 6-10, only four relapses occurred during 128 person-years, corresponding to an IRR of 0.12 (95% CI=0.03-0.33) compared with year 1. CONCLUSIONS: About 40%-50% of patients with first-episode schizophrenia will relapse despite continuous D2 blockade, apparently due to non-dopaminergic elements of the pathophysiology of the illness, as the results show that long-term dopamine receptor blockade is not associated with an increased risk of breakthrough psychosis.
引用
- Tiihonen J, Tanskanen A, Solmi M, et al. Continuous Dopamine D2 Receptor Blockade and Long-Term Outcome in First-Episode Schizophrenia. Am J Psychiatry. 2025. PMID: 39967411. doi:10.1176/appi.ajp.20240321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。